Daptomycin clinical trials
Also written Cubicin and MK-3009.
How each study uses Daptomycin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Daptomycin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Sept 2003 · CUBICIN · NDA 021572 (FDA, Drugs@FDA)
- European Union
- 19 Jan 2006 · Cubicin · EMEA/H/C/000637 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
67 studies that test it; most in 2010 (10)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 5 |
| 2010 | 10 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 29 · Other 38
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (22) · University of Zurich (3) · Merck Sharp & Dohme LLC (2) · M.D. Anderson Cancer Center (2) · AstraZeneca (2) · Duke University (2) · Novartis Pharmaceuticals (2) · University Hospital, Caen (1)
Often tested with
Tested in the same studies.
Vancomycin (6) · Cefazolin (3) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Clindamycin (1) · Linezolid (1) · Floxacillin (1) · Cloxacillin (1) · Rifampin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Daptomycin.
- Jul 2027Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?Phase 4 · West Virginia University
Studies
Open first, then newest update. How each study uses Daptomycin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 67
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?Enrolling by invitationPhase 4West Virginia UniversityNCT07148960Written as Early Dual IV Antibiotic Therapy - MRSA
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus BacteremiaRecruitingPhase 4Todd C. Lee MD MPH FIDSANCT06637332Written as Daptomycin for Injection
- Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded TrialNot yet recruitingNot applicableChang Gung Memorial HospitalNCT06189885Written as Cefazolin with Daptomycin
- Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)CompletedPhase 1University Hospital, CaenNCT04434300Written as Daptomycin
- Adjunction of Daptomycin for the Treatment of Pneumococcal MeningitisCompletedPhase 2Centre Hospitalier Universitaire DijonNCT03480191Written as Daptomycin
- Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin TreatmentTerminatedPhase 3Ruhr University of BochumNCT01199783Written as Daptomycin
- Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)CompletedPhase 2Merck Sharp & Dohme LLCNCT03643952Written as Daptomycin for Injection
- Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue InfectionsCompletedNot applicableUniversity of Maryland, BaltimoreNCT00261807Written as Daptomycin 6mg/kg/day
- Catheter Related - Gram Positive Bloodstream InfectionsCompletedPhase 2M.D. Anderson Cancer CenterNCT00467272Written as Daptomycin
- Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)TerminatedPhase 4Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00638157Written as daptomycin
- Daptomycin as Adjunctive Therapy for Staphylococcus Aureus BacteremiaCompletedPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT02972983Written as Daptomycin
- Staphylococcus Aureus Bacteremia Antibiotic Treatment OptionsCompletedPhase 3Heinrich-Heine University, DuesseldorfNCT01792804Written as Daptomycin
- Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard AntibioticsCompletedPhase 1Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00136292Written as daptomycin
- Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial PneumoniaCompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00538694Written as daptomycin
- Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. PneumoniaeCompletedPhase 3Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00540072Written as daptomycin
- PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive InfectionsCompletedPhase 1Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00679835Written as daptomycin
- Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic AntibioticsCompletedPhase 1Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01019395Written as Daptomycin
- Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion SettingTerminatedPhase 4Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT01175707Written as Daptomycin
- Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA BacteremiaTerminatedPhase 2Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)NCT00695903Written as daptomycin
- Daptomycin in Pediatric Patients With Bacterial MeningitisTerminatedPhase 1Insel Gruppe AG, University Hospital BernNCT01522105Written as Daptomycin
See all 67 studies that test Daptomycin →
Given beside what is tested · 3 — Daptomycin is usual care or a partner of the new treatment
- Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)TerminatedPhase 4West Virginia UniversityNCT05156437Written as Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONINCompletedPhase 2M.D. Anderson Cancer CenterNCT04983901Written as Daptomycin
- IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaBCompletedPhase 4Sharp HealthCareNCT02660346Written as Daptomycin
As the comparator · 8 — what is tested is compared with Daptomycin
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaCompletedPhase 3Basilea PharmaceuticaNCT03138733Written as Daptomycin
- Comparing Oral Versus Parenteral Antimicrobial TherapyTerminatedPhase 4West Virginia UniversityNCT05977868Written as Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus BacteremiaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04775953Written as Daptomycin
- Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk PatientsTerminatedPhase 4Henry Ford Health SystemNCT01734694Written as Daptomycin
- A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia TrialTerminatedPhase 3Cumberland PharmaceuticalsNCT02208063Written as Daptomycin
- Efficacy and Safety Study of Brilacidin to Treat Serious Skin InfectionsCompletedPhase 2Cellceutix CorporationNCT02052388Written as Daptomycin
- Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure InfectionsCompletedPhase 4University of CincinnatiNCT01549613Written as Daptomycin
- Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus AureusCompletedPhase 2PolyMedix, Inc.NCT01211470Written as Daptomycin
Codes
What other systems call Daptomycin · ClinicalTrials.gg INT008605
- MeSH (NLM) D017576DaptomycinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) NWQ5N31VKKDAPTOMYCINConfirmed FDA, NLM, Wikidata
- RxNorm 22299Confirmed FDA, Wikidata
- Wikidata Q418747(2R)-daptomycinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C47470DaptomycinConfirmed FDA, Wikidata
- DrugBank DB00080One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017576 | Daptomycin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | NWQ5N31VKK | DAPTOMYCIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 22299 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418747 | (2R)-daptomycin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C47470 | Daptomycin | Confirmed FDA, Wikidata |
| DrugBank | DB00080 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.